DJIA 16,804.71 -238.19 -1.40%
NASDAQ 4,422.09 -71.31 -1.59%
S&P 500 1,946.16 -26.13 -1.32%
market minute promo

Ophthotec (NASDAQ: OPHT)

37.83 -1.10 (-2.83%)

Quote as of

company name or ticker

Recent Quotes

OPHT $37.83 -2.83%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $38.74
Previous Close $38.93
Daily Range $36.46 - $38.86
52-Week Range $22.61 - $47.99
Market Cap $1.3B
P/E Ratio 10.16
Dividend (Yield) $0.00 (0.0%)
Volume 240,500
Average Daily Volume 183,177
Current FY EPS -$3.43



Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary

3 Future Biotechnology Blockbusters?

Medivation, Ophthotech, and Portola all have potential blockbusters on their hands.

Sector Update: Health-Care Shares Mixed in Pre-Market Trade

Sector Update: Health Care

Ophthotech's (OPHT) CEO David Guyer on Q2 2014 Results - Earnings Call Transcript

Benzinga's Top Initiations

Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About

The Fed thinks biotech stocks are overvalued. Here's where they're wrong.

Is Opthotech Your Next Multibagger Stock?

Opthotech is working on a treatment for wet AMD that could have sales potential equal to that of Novartis' Lucentis or Regeneron's (REGN) Eylea.

Ohr Pharmaceutical: Questionable Analyst Activity

Phase II Calamity Dooms Ohr's Eye Drops

3 Stocks Near 52-Week Highs Worth Selling

Are these three stocks sells or belles? You be the judge!

See More OPHT News...